Cancer Research Institute (CRI) shared a post on LinkedIn:
“Can engineered bacteria revolutionize cancer treatment?
A new article from authors including CRI’s Director of Scientific Affairs, Samik Upadhaya, CRI Lloyd J. Old STAR Dr. Tal Danino of Columbia University, and former Associate of the CRI Anna-Maria Kellen Clinical Accelerator and Venture Fund, Dr. Ana Rosa Sáez Ibáñez, just published in Nature Biotechnology explores the potential of bacteria-based cancer therapy.
Key Highlights:
- 30 years of preclinical, clinical, and commercial advancements in bacterial cancer treatments
- Insights into how synthetic biology is shaping microbial immunotherapy
- Future directions for customizable, tunable, and effective tumor-targeting bacterial medicines
This must-read review uncovers the latest trends in cancer-fighting bacteria and their potential to become an indispensable tool in oncology.
Discover.”
Authors: Edward R. Ballister, Alexander Michels, Rosa L. Vincent, Lior Kreindler, Sreyan Chowdhury, Samik Upadhaya, Ana Rosa Saez-Ibañez, Tao Tu, Juraj Gottweis, Tal Danino
